Organic Bioelectronics enables patient-control of medical treatment
|Coordinator||SICS EAST SWEDISH ICT AB - SICS East Swedish ICT|
|Funding from Vinnova||SEK 500 000|
|Project duration||April 2016 - December 2016|
|Venture||Challenge-Driven Innovation – Stage 1 initiation|
|Call||Challenge-Driven Innovation - Stage 1 Initiation 2016 (spring)|
Purpose and goal
The project had three goals: to select the appropriate medical indication for the development of the first product, to create a development plan for this product for the project´s next phase, as well as to form an adequate consortium to maximise the chances to succeed with development. These three goals we have achieved. Contacts with industry have confirmed strong interest in pioneering technologies, such as ours, that facilitate individualized digitized healthcare, both in a holistic perspective but also, more importantly, for the identified indications.
Expected results and effects
The scientists involved have for 10 years had cooperation with physicians in many specialty areas. Based on this, and new contacts, we have identified 4 areas where our technology can solve significant clinical problems. Regulatory evaluation proposed the relief of chronic peripheral pain to be the easiest for early successful proof-of-concept. Clinical researchers at Region Östergötland have been engaged. Goal for the next phase is to have approval for a clinical research study where clinicians specialized in pain defines the requirements for the performance of the prototype.
Planned approach and implementation
Four workshops were planned and held. Joint planning and unambiguous responsibilities gave great transparency and basis for consensus. Weekly meetings were planned and carried out as the project leader´s contact with the partner representatives. We have succeeded in linking high-end clinical research centres as partners (Region Östergötland) for the next phase. We have established cooperation with stakeholders for additional indications, and are now formalizing cooperation with two foreign entities. The industry shows interest, and we believe in a signed agreement shortly.